Tafolecimab
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia[1].
Product Specifications
CAS Number
[2225109-03-3]
Product Name Alternative
IBI-306
UNSPSC
12352203
Target
PCSK9
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/tafolecimab.html
Purity
95.04
Solubility
10 mM in DMSO
Smiles
[Tafolecimab]
Molecular Weight
(145.34 kDa)
References & Citations
[1]Y Cui, et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects .European Heart Journal, Volume 41, Issue Supplement_2, November 2020.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
054356-01 10 µg
Von Willebrand Factor A Domain Containing Protein 1 (vWA1), Recombinant, Mouse, His-Tag, T7-Tag
Ask
View Details 054356-02 50 µg
Von Willebrand Factor A Domain Containing Protein 1 (vWA1), Recombinant, Mouse, His-Tag, T7-Tag
Ask
View Details